Findings

What do systematic reviews say?

200 questions · 203 findings · 8 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 82 · 40.4%GRADE not reported 10 · 4.9%Very low 25 · 12.3%Low 37 · 18.2%Moderate 35 · 17.2%High 14 · 6.9%

Imiquimod vs placebo

Dose reductions · women with high‐grade VIN

The review found no eligible studies for this question.

1 finding from 1 review

Medical interventions for high‐grade vulval intraepithelial neoplasia 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Imiquimod vs cidofovir

Pain ‐ Any grade · women with high‐grade VIN

The review found no eligible studies for this question.

1 finding from 1 review

Medical interventions for high‐grade vulval intraepithelial neoplasia 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Imiquimod vs cidofovir

Fatigue · women with high‐grade VIN

The review found no eligible studies for this question.

1 finding from 1 review

Medical interventions for high‐grade vulval intraepithelial neoplasia 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Imiquimod vs cidofovir

Headache · women with high‐grade VIN

The review found no eligible studies for this question.

1 finding from 1 review

Medical interventions for high‐grade vulval intraepithelial neoplasia 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Imiquimod vs cidofovir

Treatment discontinuation · women with high‐grade VIN

The review found no eligible studies for this question.

1 finding from 1 review

Medical interventions for high‐grade vulval intraepithelial neoplasia 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Hydrogel spacer vs no intervention

Mean GI symptom scores · Men undergoing RT for prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Hydrogel spacer vs no intervention

Acute and late GI toxicity (grade 2+) · Men undergoing RT for prostate cancer

Summary of findings: Hydrogel spacer showed no clear difference in acute and late GI toxicity (grade 2+) compared with no intervention (low certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 0.51 [0.08, 3.38]
2 studies · 289 participants
Low

Summary of findings: Hydrogel spacer vs no intervention

Diarrhoea (grade 2+) · Men undergoing RT for prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Hydrogel spacer vs no intervention

QoL · Men undergoing RT for prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Corticosteroids vs placebo

Mean GI symptom scores · Men with prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Corticosteroids vs placebo

Acute and late GI toxicity (grade 2+) · Men with prostate cancer

It is very uncertain whether summary of findings: Corticosteroids changes acute and late GI toxicity (grade 2+) compared with placebo (very low certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 0.85 [0.62, 1.15]
1 study · 126 participants
Very low

Corticosteroids vs placebo

Diarrhoea (grade 2+) · Men with prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Corticosteroids vs placebo

QoL · Men with prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Sodium butyrate vs placebo

Mean GI symptom scores · Men undergoing RT for prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Sodium butyrate vs placebo

Acute and late GI toxicity (grade 2+) · Men undergoing RT for prostate cancer

Summary of findings: Sodium butyrate showed no clear difference in acute and late GI toxicity (grade 2+) compared with placebo (moderate certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 0.91 [0.41, 1.98]
1 study · 79 participants
Moderate

Summary of findings: Sodium butyrate vs placebo

Diarrhoea (grade 2+) · Men undergoing RT for prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Sodium butyrate vs placebo

QoL · Men undergoing RT for prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Magnesium oxide vs placebo

Mean GI symptom scores (during RT) · Men with prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Magnesium oxide vs placebo

Acute and late GI toxicity (grade 2+) · Men with prostate cancer

Summary of findings: Magnesium oxide showed no clear difference in acute and late GI toxicity (grade 2+) compared with placebo (moderate certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 1.7 [0.87, 3.31]
1 study · 92 participants
Moderate

Summary of findings: Magnesium oxide vs placebo

Diarrhoea (grade 2+) · Men with prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found